Abstract:β-thalassemia, caused by mutations in the human hemoglobin β (HBB) gene, is one of the most common genetic diseases in the world. The HBB −28(A>G) mutation is one of the five most common mutations in Chinese patients with β-thalassemia. However, few studies have been conducted to understand how this mutation affects the expression of pathogenesis-related genes, including globin genes, due to limited homozygote clinical materials. Therefore, we developed an efficient technique using CRISPR/Cas9 combined with asymmetric single-stranded oligodeoxynucleotides (assODNs) to generate a K562 cell model with HBB −28(A>G) named K562–28(A>G). Then, we systematically analyzed the differences between K562–28(A>G) and K562 at the transcriptome level by high-throughput RNA-seq before and after erythroid differentiation. We found that the HBB −28(A>G) mutation not only disturbed the transcription of HBB, but also decreased the expression of HBG, which may further aggravate the thalassemia phenotype and partially explain the more severe clinical outcome of β-thalassemia patients with the HBB −28(A>G) mutation. Moreover, we found that the K562–28(A>G) cell line is more sensitive to hypoxia and shows a defective erythrogenic program compared with K562 before differentiation. Importantly, all abovementioned abnormalities in K562–28(A>G) were reversed after correction of this mutation with CRISPR/Cas9 and assODNs, confirming the specificity of these phenotypes. Overall, this is the first time to analyze the effects of the HBB −28(A>G) mutation at the whole-transcriptome level based on isogenic cell lines, providing a landscape for further investigation of the mechanism of β-thalassemia with the HBB −28(A>G) mutation.

Activation of γ-globin expression by a common variant disrupting IKAROS-binding motif in β-thalassemia

A Genetic Variant Ameliorates Β-Thalassemia Severity by Epigenetic-Mediated Elevation of Human Fetal Hemoglobin Expression

Activation of γ-globin expression by LncRNA-mediated ERF promoter hypermethylation in β-thalassemia

Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin

3’HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

Identification and characterization of CHD4-associated eRNA as a novel modulator of fetal hemoglobin levels in β-thalassemia

3′HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia

Genetic modifications of EGLN1 reactivate HbF production in β0-thalassemia/HbE

Long noncoding RNA HBBP1 enhances γ-globin expression through the ETS transcription factor ELK1

Transcriptome Analyses of β-Thalassemia −28(A>G) Mutation Using Isogenic Cell Models Generated by CRISPR/Cas9 and Asymmetric Single-Stranded Oligodeoxynucleotides (assODNs)

Proteomics Screening Uncovers HMGA1 As a Promising Negative Regulator for Γ-Globin Expression in Response to Decreased Β-Globin Levels

Multi-Omics Analysis in β-Thalassemia Using an HBB Gene-Knockout Human Erythroid Progenitor Cell Model

Genome editing in K562 cells suggests a functional role for the XmnI Gg polymorphism: a widely used genetic marker in β-thalassemia and sickle cell disease patients

Long noncoding RNA <i>HBBP1</i> enhances -globin expression through the ETS transcription factor ELK1

Unravelling the Complexity of the +33 C>G [HBB:c.-18C>G] Variant in Beta Thalassemia

Characterization of a novel HBB:c.194dup variant of the β-globin gene combined with six alpha genes

Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait

Fetal Hemoglobin Regulation in Beta-Thalassemia

Identification of a PRMT5-dependent repressor complex linked to silencing of human fetal globin gene expression.

Structural basis for human ZBTB7A action at the fetal globin promoter